Expert en Analyse de Données Biologiques
Solutions de Recherche Data-Driven pour Vos Données Biologiques
Besoin d’une Analyse de Données Biologiques Experte ?
AltraBio est expert en analyse de données biologiques. Nous utilisons l’IA et les statistiques avancées pour extraire des insights de vos données cytométriques, omiques et médicales.
Notre expertise fait de nous un partenaire R&D pour les leaders des secteurs pharmaceutique, médical, diagnostic et dermo-cosmétique.
Découvrez nos services :
Notre expertise en Analyse de données biologiques
Partenariats collaboratifs
Développement d’outils computationnels pour l’analyse de données biologiques dans des consortiums régionaux, nationaux et internationaux.
Exemples de nos projets actuels et achevés :
-
SCAnIO : Plateforme Économique pour l’Analyse de Cellules Uniques en Immuno-Oncologie.
-
MEMOIRE : Modélisation Multi-Échelle de la Réponse Immune des Lymphocytes T CD8.
-
PEST-BIN : Stratégies Innovantes contre les Infections Bactériennes.
-
SIGNATURE : Étude des Cellules Uniques dans les Maladies Auto-Immunes Inflammatoires
Sous-traitance
Nous fournissons des services d’analyse de données biologiques pour des entreprises et des hôpitaux universitaires.
-
Des centaines de projets achevés.
-
Nos clients réguliers incluent des entreprises pharmaceutiques de premier plan et des leaders en cosmétiques.
Pourquoi choisir AltraBio pour l’analyse de vos données biologiques ?
« Even in the age of generative AI, Altrabio’s two decades of expertise in maths, stats, biology, and medical science remain invaluable. They don’t just talk, they do. No flashy marketing, no inflated costs, just solid, thoughtful work from study design to actionable insights. A trusted partner, for twenty years, in a world full of noise. Highly recommend working with them to make real sense of your complex biomedical and omics data. »
« Top of the field »
« They are highly efficient and agile; you won’t interact with much people, so they are quick to respond and provide high-quality service »
« If there is some problem, or troubleshooting is necessary, or some change in the workflow, they are very flexible.»
« They do cutting-edge work, we clearly like the innovation part »
« In clinical trials, we could get thousands of samples for different panels… The scale is clearly so big, not many companies can do this kind of work in production mode, on the labor scale »
« They fit clients’ need. »
« Exceptional »
« We really appreciate AltraBio because they provide one-stop full service, so we don’t need to worry about a lot of former problems, and also quality of results »
« Supervised approach is really a mature approach, I think there is an absolute need for having this solution… »
« The quality of the results we got from AB was quite remarkable in the good »
« AltraBio is viewed as automating subject matter experts, with the ability to do the same work. It allows us to free up subject matter experts at scale so a subject matter expert doesn’t have to spend as much time doing gating or reviewing gatings, and it all hinges on the quality that they provide. So for us, that’s the biggest selling point; the quality allow us to be able to say, OK this technology is almost as good as subject matter experts in this domain, and the pricing and the speed make it such that it becomes a feasible solution for us to say we can free up the scientists to do other things and this part can be handled by AltraBio. »
« Automated gating is there… In 2018, when automated gating was discussed at CYTO, some people stood up and said: “No! This is not going to work. Gating has been done by scientists & experts, and you can’t just put a computer to do their job.” We know now that it is not true because the Altrabio’s solutions are now doing it. It is pretty amazing. »
« This is accurate; we can use it at scale, so we don’t have to do the manual gating. »
« They do that extra bit of QC on their hand; they also check the transfers and put that extra effort in to make sure that what we do is accurate »
« The work we do with AltraBio is a partnership. I’ll make an example of the last analysis that we did; there were some timelines that needed to be met and they stepped in and said “OK we‘ll get this done in a few days”, not in a week, not in a month … When you have that relationship, when you understand the value and you understand the timelines of the customer, that felt really like a partnership and I think we’re heading in that direction… »
Découvrez comment nos solutions sur mesure en analyse de données biologiques peuvent accélérer vos projets de R&D.
Nouvelles
mars 2026
Analyse omique dermocosmétique : AltraBio au Cosmetotest
Le symposium international Cosmetotest est le rendez-vous annuel incontournable [...]
Transcriptomique vaccin ARNsa : Analyse de l’essai COVAC1
Si la pandémie de COVID-19 a prouvé l'efficacité de [...]
février 2026
Analyse de variants SNV : Le secret des couleurs du poisson-clown | AltraBio
Les motifs colorés des animaux jouent un rôle crucial [...]
Le Machine Learning identifie des biomarqueurs pronostiques FPI clés dans les essais ISABELA
Introduction Une étude majeure récemment publiée dans ERJ Open [...]
Dernières Publications
2014
Idbaih, Ahmed; Mokhtari, Karima; cois Emile, Jean-Franc; Galanaud, Damien; Belaid, Hayat; Bernard, Simon; Benameur, Neila; Barlog, Vlad-Ciprian; Psimaras, Dimitri; Donadieu, Jean; Carpentier, Catherine; Martin-Duverneuil, Nadine; Haroche, Julien; Feuvret, Loic; Zahr, Noel; Delattre, Jean-Yves; Hoang-Xuan, Kh^e
Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib Article de journal
Dans: Neurology, vol. 83, no. 16, p. 1478–1480, 2014.
@article{Idbaih2014-pa,
title = {Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib},
author = {Ahmed Idbaih and Karima Mokhtari and Jean-Franc cois Emile and Damien Galanaud and Hayat Belaid and Simon Bernard and Neila Benameur and Vlad-Ciprian Barlog and Dimitri Psimaras and Jean Donadieu and Catherine Carpentier and Nadine Martin-Duverneuil and Julien Haroche and Loic Feuvret and Noel Zahr and Jean-Yves Delattre and Kh^e Hoang-Xuan},
doi = {10.1212/WNL.0000000000000880},
year = {2014},
date = {2014-10-01},
urldate = {2014-10-01},
journal = {Neurology},
volume = {83},
number = {16},
pages = {1478--1480},
publisher = {Ovid Technologies (Wolters Kluwer Health)},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Idbaih, Ahmed; Mokhtari, Karima; Emile, Jean-François; Galanaud, Damien; Belaid, Hayat; de Bernard, Simon; Benameur, Neila; Barlog, Vlad-Ciprian; Psimaras, Dimitri; Donadieu, Jean; Carpentier, Catherine; Martin-Duverneuil, Nadine; Haroche, Julien; Feuvret, Loic; Zahr, Noel; Delattre, Jean-Yves; Hoang-Xuan, Khê
Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib Article de journal
Dans: Neurology, vol. 83, no. 16, p. 1478–1480, 2014, ISSN: 1526-632X.
@article{pmid25209580,
title = {Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib},
author = {Ahmed Idbaih and Karima Mokhtari and Jean-François Emile and Damien Galanaud and Hayat Belaid and Simon de Bernard and Neila Benameur and Vlad-Ciprian Barlog and Dimitri Psimaras and Jean Donadieu and Catherine Carpentier and Nadine Martin-Duverneuil and Julien Haroche and Loic Feuvret and Noel Zahr and Jean-Yves Delattre and Khê Hoang-Xuan},
doi = {10.1212/WNL.0000000000000880},
issn = {1526-632X},
year = {2014},
date = {2014-10-01},
urldate = {2014-10-01},
journal = {Neurology},
volume = {83},
number = {16},
pages = {1478--1480},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Daussy, Cécile; Faure, Fabrice; Mayol, Katia; Viel, Sébastien; Gasteiger, Georg; Charrier, Emily; Bienvenu, Jacques; Henry, Thomas; Debien, Emilie; Hasan, Uzma A; Marvel, Jacqueline; Yoh, Keigyou; Takahashi, Satoru; Prinz, Immo; de Bernard, Simon; Buffat, Laurent; Walzer, Thierry
T-bet and Eomes instruct the development of two distinct natural killer cell lineages in the liver and in the bone marrow Article de journal
Dans: J Exp Med, vol. 211, no. 3, p. 563–577, 2014, ISSN: 1540-9538.
@article{pmid24516120,
title = {T-bet and Eomes instruct the development of two distinct natural killer cell lineages in the liver and in the bone marrow},
author = {Cécile Daussy and Fabrice Faure and Katia Mayol and Sébastien Viel and Georg Gasteiger and Emily Charrier and Jacques Bienvenu and Thomas Henry and Emilie Debien and Uzma A Hasan and Jacqueline Marvel and Keigyou Yoh and Satoru Takahashi and Immo Prinz and Simon de Bernard and Laurent Buffat and Thierry Walzer},
doi = {10.1084/jem.20131560},
issn = {1540-9538},
year = {2014},
date = {2014-03-01},
urldate = {2014-03-01},
journal = {J Exp Med},
volume = {211},
number = {3},
pages = {563--577},
abstract = {Trail(+)DX5(-)Eomes(-) natural killer (NK) cells arise in the mouse fetal liver and persist in the adult liver. Their relationships with Trail(-)DX5(+) NK cells remain controversial. We generated a novel Eomes-GFP reporter murine model to address this question. We found that Eomes(-) NK cells are not precursors of classical Eomes(+) NK cells but rather constitute a distinct lineage of innate lymphoid cells. Eomes(-) NK cells are strictly dependent on both T-bet and IL-15, similarly to NKT cells. We observed that, in the liver, expression of T-bet in progenitors represses Eomes expression and the development of Eomes(+) NK cells. Reciprocally, the bone marrow (BM) microenvironment restricts T-bet expression in developing NK cells. Ectopic expression of T-bet forces the development of Eomes(-) NK cells, demonstrating that repression of T-bet is essential for the development of Eomes(+) NK cells. Gene profile analyses show that Eomes(-) NK cells share part of their transcriptional program with NKT cells, including genes involved in liver homing and NK cell receptors. Moreover, Eomes(-) NK cells produce a broad range of cytokines, including IL-2 and TNF in vitro and in vivo, during immune responses against vaccinia virus. Thus, mutually exclusive expression of T-bet and Eomes drives the development of different NK cell lineages with complementary functions.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Financement





